Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Drug checking

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    13 result(s) found for: Drug checking. Displaying page 1 of 1.
    EudraCT Number: 2012-004053-88 Sponsor Protocol Number: EuroNet-PHL-C2 Start Date*: 2015-07-01
    Sponsor Name:Justus-Liebig-University Giessen
    Full Title: EuroNet-Paediatric Hodgkin’s Lymphoma Group Second International Inter-Group Study for Classical Hodgkin’s Lymphoma in Children and Adolescents
    Medical condition: Hodgkin lymphoma in children and adolescents
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) AT (Completed) CZ (Completed) ES (Ongoing) IT (Prematurely Ended) NL (Completed) DK (Prematurely Ended) FR (Ongoing) PL (Prematurely Ended) FI (Completed) GB (GB - no longer in EU/EEA) SE (Completed) NO (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-000300-28 Sponsor Protocol Number: D081DC00007 Start Date*: 2017-02-24
    Sponsor Name:AstraZeneca
    Full Title: A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate C...
    Medical condition: Metastatic castration-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) DK (Completed) NO (Completed) ES (Completed) AT (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-015162-57 Sponsor Protocol Number: P06153 Start Date*: 2011-03-02
    Sponsor Name:Schering-Plough Research Institute, a division of Schering Corporation
    Full Title: A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3, Protocol No. P06153)
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Prematurely Ended) AT (Prematurely Ended) ES (Prematurely Ended) CZ (Prematurely Ended) LT (Prematurely Ended) IT (Prematurely Ended) LV (Prematurely Ended) NL (Completed) SE (Prematurely Ended) BG (Completed) PT (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-010895-64 Sponsor Protocol Number: E2090-E039-401 Start Date*: 2009-05-31
    Sponsor Name:Eisai s.r.l.
    Full Title: A superiority, randomized, open-label, multi-center study to compare the efficacy and safety of adjunctive zonisamide vs replacement with zonisamide of the last added antiepileptic drug in patients...
    Medical condition: Patients with localization-related epilepsy, who have added a second drug to the monotherapy, haven’t obtained an adequate reduction of seizure frequency with this combination and have responded to...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065337 Focal epilepsy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004318-16 Sponsor Protocol Number: DAS181-3-01 Start Date*: 2020-01-16
    Sponsor Name:Ansun Biopharma, Inc.
    Full Title: A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects
    Medical condition: Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10033796 Parainfluenzae viral infections HLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DK (Prematurely Ended) FR (Prematurely Ended) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000255-13 Sponsor Protocol Number: 11-019 Start Date*: 2012-06-20
    Sponsor Name:Portola Pharmaceuticals, Inc.
    Full Title: Multicenter, Randomized, Active-Controlled Efficacy And Safety Study Comparing Extended Duration Betrixaban With Standard Of Care Enoxaparin For The Prevention Of Venous Thromboembolism In Acute Me...
    Medical condition: Prophylaxis of venous thromboembolism
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004865 10049909 Venous thromboembolism prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) LV (Completed) DE (Completed) ES (Completed) GB (Completed) PL (Completed) LT (Completed) AT (Completed) DK (Completed) CZ (Completed) BG (Completed) IT (Completed) FI (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2017-002544-32 Sponsor Protocol Number: UCL/15/0515 Start Date*: 2018-03-01
    Sponsor Name:University College London
    Full Title: A phase II study of nivolumab monotherapy in patients with relapsed/refractory Hodgkin lymphoma, fit for autologous stem cell transplant, who fail to reach complete metabolic remission after first ...
    Medical condition: Relapsed/refractory Hodgkin lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020266 Hodgkin's disease recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020267 Hodgkin's disease refractory PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2010-023804-28 Sponsor Protocol Number: P09-10/ BF2.649 Start Date*: 2011-07-29
    Sponsor Name:Bioprojet
    Full Title: An open-label naturalistic pragmatic study to assess the long term safety of BF2.649 (Pitolisant) in the treatment of Excessive Daytime Sleepiness (EDS) in narcolepsy (12 months follow-up).
    Medical condition: Narcolepsy
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10028715 Narcolepsy with cataplexy LLT
    13.1 10029205 - Nervous system disorders 10028713 Narcolepsy PT
    13.1 10029205 - Nervous system disorders 10048323 Cataplexy aggravated LLT
    13.1 10029205 - Nervous system disorders 10007737 Cataplexy PT
    13.1 10029205 - Nervous system disorders 10048322 Narcolepsy aggravated LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2011-006086-17 Sponsor Protocol Number: 55005646 Start Date*: 2012-07-10
    Sponsor Name:Maria Fernanda Pedrero Escalas
    Full Title: "Effectiveness of homeopathic treatment (Agraphis nutans 5CH, Thuya occidentalis 5CH, Kalium muriaticum and Arsenicum iodatum 9CH 9CH) as adjuvant secretory otitis in children"
    Medical condition: Pediatric patients aged 2 months to 12 years presenting secretory otitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10033072 Otitis externa PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003717-29 Sponsor Protocol Number: D4193C00003 Start Date*: 2015-08-10
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736 in Combination with Tremelimumab in Patients with Recurrent or Metasta...
    Medical condition: Patients with recurrent or metastatic PD-L1-negative squamous cell carcinoma of the head and neck (SCCHN)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) DE (Completed) GB (Completed) CZ (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-001655-31 Sponsor Protocol Number: AL3818-US-004 Start Date*: 2017-12-20
    Sponsor Name:ADVENCHEN LABORATORIES, LLC
    Full Title: A Phase III Study of AL3818 (Anlotinib) Hydrochloride Monotherapy in Subjects with Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma
    Medical condition: Metastatic or advanced alveolar soft part sarcoma, leiomyosarcoma and synovial sarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024189 Leiomyosarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001882 Alveolar soft part sarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042863 Synovial sarcoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2010-019859-21 Sponsor Protocol Number: PMR-EC-1501 Start Date*: 2011-05-05
    Sponsor Name:Astellas Pharma Europe Ltd.
    Full Title: A Phase II, Open Label, Parallel Group, Multi-Center Study to Compare the Pharmacokinetics of Tacrolimus in Adult Subjects Undergoing Primary Allograft Transplantation Receiving an Advagraf® or Pro...
    Medical condition: Prophylaxis of primary heart, lung, pancreas, (including simultaneous pancreas kidney [SPK]) organ transplant rejection.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10050433 Prophylaxis against lung transplant rejection LLT
    12.1 10050432 Prophylaxis against heart transplant rejection LLT
    12.1 10050435 Prophylaxis against pancreas transplant rejection LLT
    12.1 10050438 Prophylaxis against renal and pancreas transplant rejection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) GB (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002232-85 Sponsor Protocol Number: 5172-017 Start Date*: 2013-01-15
    Sponsor Name:Merck Sharp & Dohme Corp.
    Full Title: A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects With Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in ...
    Medical condition: Hepatitis C Virus Infection (HCV)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) IT (Prematurely Ended) SE (Completed) GB (GB - no longer in EU/EEA) DK (Completed) HU (Completed) ES (Completed) FI (Completed) NL (Completed) LT (Completed) EE (Completed) CZ (Completed) NO (Completed) AT (Completed) PL (Completed) GR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 02:24:01 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA